An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure.
Acute hepatic failure (AHF) is a severe liver injury accompanied by hepatic encephalopathy which causes multiorgan failure with an extremely high mortality rate, even if intensive care is provided. Management of severe AHF continues to be one of the most challenging problems in clinical medicine. Liver transplantation has been shown to be the most effective therapy, but the procedure is limited by shortage of donor organs. Although a number of clinical trials testing different liver assist devices are under way, these systems alone have no significant effect on patient survival and are only regarded as a useful approach to bridge patients with AHF to liver transplantation. As a result, reproducible experimental animal models resembling the clinical conditions are still needed. The three main approaches used to create an animal model for AHF are: surgical procedures, toxic liver injury and infective procedures. Most common models are based on surgical techniques (total/partial hepatectomy, complete/transient devascularization) or the use of hepatotoxic drugs (acetaminophen, galactosamine, thioacetamide, and others), and very few satisfactory viral models are available. We have recently developed a viral model of AHF by means of the inoculation of rabbits with the virus of rabbit hemorrhagic disease. This model displays biochemical and histological characteristics, and clinical features that resemble those in human AHF. In the present article an overview is given of the most widely used animal models of AHF, and their main advantages and disadvantages are reviewed.
Tuñón
María-Jesús
MJ
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas (CIBERehd) and Institute of Biomedicine, University of León, León, Spain. mjtung@unileon.es
Alvarez
Marcelino
M
Culebras
Jesús-M
JM
González-Gallego
Javier
J
D000082:Acetaminophen / Q000633:toxicity; D000818:Animals; D002251:Carbon Tetrachloride / Q000633:toxicity; D004195:Disease Models, Animal; D005688:Galactosamine / Q000633:toxicity; D006498:Hepatectomy / Q000379:methods; D006801:Humans; D017114:Liver Failure, Acute / Q000209:etiology / Q000628:therapy; D008115:Liver Regeneration / Q000502:physiology
D000082:Acetaminophen; D005688:Galactosamine; D002251:Carbon Tetrachloride